Adrian Chrastina

Sep 3, 2024 | biorxiv.org | Tapas K. Nayak |Adrian Chrastina |Jose Luis Valencia |José A. Valencia |José Parrilla València |Robert Yedidsion

AbstractModern medicine seeks precision targeting, imaging and therapy to maximize efficacy and avoid toxicities. Nanoparticles (NPs) have tremendous, yet unmet clinical potential to carry and deliver imaging and therapeutic agents systemically with tissue precision. But their size contributes to unwanted rapid scavenging by the reticulo-endothelial system (RES) and poor penetration of key endothelial cell (EC) barriers, both limiting target-tissue uptake, safety and efficacy.